BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Acrotech Biopharma readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Acrotech Biopharma's drugs run\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07173478-1444@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Moizerto / Adquey (difamilast): Phase 3 readout est. (NCT07173478)
DESCRIPTION:Moizerto / Adquey (difamilast)\, phase 3\, Atopic Dermatitis.\n
 Study: A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam
  to the Vehicle in Adult Patients With Atopic Dermatitis\nEstimated primar
 y completion: December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/difamilast#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07173478
URL:https://assetmemo.bio/drug/difamilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07184645-1444@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Moizerto / Adquey (difamilast): Phase 3 readout est. (NCT07184645)
DESCRIPTION:Moizerto / Adquey (difamilast)\, phase 3\, Atopic Dermatitis.\n
 Study: A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atop
 ic Dermatitis\nEstimated primary completion: February 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/difamilast#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07184645
URL:https://assetmemo.bio/drug/difamilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06072131-3412@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Belinostat: Phase 3 readout est. (NCT06072131)
DESCRIPTION:Belinostat\, phase 3\, Peripheral T-Cell Lymphoma.\nStudy: To E
 valuate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP
  Alone in PTCL\nEstimated primary completion: July 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/belinostat#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06072131
URL:https://assetmemo.bio/drug/belinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
